{"filings":[{"id":501396,"accession_number":"0001493152-26-024219","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2026-05-18T21:07:52+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Palatin Technologies to transfer stock listing from NYSE American to Nasdaq Capital Market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntary withdrawal from NYSE American; last trade expected on NYSE May 28, 2026.","Common stock begins trading on Nasdaq Capital Market on May 29, 2026 under symbol PTN.","Nasdaq has approved the listing; no action required from existing stockholders.","CEO states move will improve visibility, trading liquidity, and institutional exposure.","Company continues to advance MC4R programs with IND for injectable agonist targeted for Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132238,"accession_number":"0001493152-25-028569","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K/A","filed_at":"2025-12-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Palatin board adopts annual say-on-pay vote after stockholder advisory approval","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders voted, on advisory basis, to hold say-on-pay vote every year at July 25, 2025 annual meeting.","Board determined to include annual advisory vote on executive compensation in proxy materials until next required frequency vote.","Amendment filed solely to disclose board's decision on frequency of future say-on-pay votes.","No other changes from original 8-K filed July 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132240,"accession_number":"0001654954-25-012928","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin closes $18.2M public offering, regains NYSE American listing compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed upsized public offering of 2,795,384 shares/pre-funded warrants and warrants at combined $6.50, gross proceeds $18.2M.","Regained compliance with NYSE American stockholders’ equity rule; trading resumed November 12, 2025 under symbol PTN.","Proceeds to support obesity program development and for working capital and general corporate purposes.","Offering included participation from CEO, CFO/COO, and certain board members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132239,"accession_number":"0001654954-25-012641","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Palatin prices $15.8M public offering; NYSE American listing resumes Nov 12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced upsized public offering of 2.43M shares at $6.50/unit; gross proceeds ~$15.8M.","Series J warrants ($6.50) expire 31 days after FDA accepts IND for obesity program; Series K ($8.125) expire 5 years but terminate early if J not exercised.","Underwriters granted 45-day option for additional 364,615 shares; closing expected Nov 12, 2025.","Proceeds to fund obesity program and working capital; potential additional $15.8M upon cash exercise of Series J warrants.","NYSE American listing resumes Nov 12 under PTN; compliance regained after reverse split and $8.8M revenue from Boehringer Ingelheim."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148818,"accession_number":"0001654954-25-010973","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin earns €5.5M milestone payment from Boehringer Ingelheim in retinal disease collaboration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Achieved research milestone in collaboration with Boehringer Ingelheim, triggering €5.5M ($6.5M) payment to Palatin.","Collaboration, announced Aug 18, 2025, targets first-in-class melanocortin receptor treatment for diabetic retinopathy and diabetic macular edema.","Palatin eligible for up to €278M ($328M) in success-based milestones plus tiered royalties on net sales from the collaboration.","Upfront payment of €2M already received; total near-term research milestones of €18M including the €5.5M achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148817,"accession_number":"0001654954-25-010576","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Palatin begins OTCQB trading under PTNT after 1-for-50 reverse split; delisted from NYSE American","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["NYSE American suspended trading and initiated delisting on May 7, 2025, due to low stock price.","Reverse split 1-for-50 effective; shares traded under PTNTD for 20 days, then PTNT starting Sept 10, 2025.","Company now trades solely on OTCQB Market; no longer listed on NYSE American.","Stock previously traded on NYSE American under symbol PTN.","Delisting and reverse split reflect ongoing low-pricing and shareholder dilution concerns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148816,"accession_number":"0001654954-25-009743","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Palatin signs up to €280M collaboration with Boehringer for retinal disease therapies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["€2M upfront, up to €18M near-term milestones, up to €260M in regulatory/commercial milestones plus tiered royalties.","Collaboration focuses on melanocortin receptor agonists for diabetic retinopathy and DME; Boehringer funds two-year research.","Palatin assigned patent rights to Boehringer; potential first-in-class treatment targeting inflammation, vascular dysfunction, neurodegeneration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148812,"accession_number":"0001654954-25-009330","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K/A","filed_at":"2025-08-11T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Palatin Technologies to effect 1-for-50 reverse stock split on August 11, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective after market on August 11; split-adjusted trading on OTCQB begins August 12.","NYSE American delisted company on May 7 due to low selling price; stock now trades on OTCQB as PTNT.","FINRA approval delayed the reverse split; company expects approval after market August 11."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148815,"accession_number":"0001654954-25-009290","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Palatin Technologies announces 1-for-50 reverse stock split effective Aug 8, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split at 1-for-50 ratio effective 5:00 p.m. ET on August 8, 2025.","Common stock to trade on OTCQB Market (symbol PTNT) on a split-adjusted basis from Aug 11.","Ticker temporarily changes to PTNTD for 20 trading days post-split.","NYSE American delisted the stock on May 7, 2025 due to low selling price; now on OTCQB.","Stockholders receive cash for fractional shares; CUSIP changes to 696077 601."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148814,"accession_number":"0001654954-25-008579","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Palatin shareholders approve reverse stock split (1:50-1:100) and increase shares for equity awards","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split (1:50-1:100) approved; 12.4M for, 8.2M against. Board to set exact ratio.","Stockholders approved adding 3M shares to 2011 Stock Incentive Plan; 4.9M for, 3.2M against.","All four director nominees (Spana, Prendergast, Dunton, Morris) elected with ~7M votes each.","Issuance of shares upon exercise of Series B, D, and I warrants approved by stockholders.","Advisory vote favors annual say-on-pay frequency; executive compensation for FY2024 approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148813,"accession_number":"0001654954-25-007872","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"NYSE American Panel affirms delisting of Palatin Technologies; stock trades on OTCQB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Panel unanimously affirmed delisting under Sections 1003(a) and 1003(f)(v) due to low selling price of common stock.","NYSE American suspended trading on May 7, 2025; stock has traded on OTCQB under symbol PTNT since June 9, 2025.","Company intends to appeal Panel decision to the full Committee for Review; appeal hearing expected in late August or September 2025.","Company is actively working to resolve listing deficiencies prior to the appeal hearing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167694,"accession_number":"0001654954-25-006936","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["1.01","5.03","3.02","9.01"],"status":"ready","headline":"Palatin Technologies delisted from NYSE American; raises $340K in insider private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NYSE American commenced delisting proceedings; common stock suspended May 7, 2025. Now trades on OTCQB under PTNT.","On June 10, 2025, entered private placement with CEO, CFO, and two directors for $340,000 gross proceeds.","Issued Series D Preferred Stock convertible at $0.11/share and warrants exercisable at $0.11, subject to stockholder approval.","Proceeds to be used for general working capital purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167693,"accession_number":"0001654954-25-005296","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["1.01","3.01","8.01","9.01"],"status":"ready","headline":"Palatin Technologies delisted from NYSE American; reduced offering raises only $1.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NYSE American suspended trading and commenced delisting proceedings due to low stock price; shares transitioned to OTC Pink under 'PTNT'.","Original $11.5M offering (76,666,667 shares at $0.15) collapsed after delisting; net proceeds fell to $1.1M.","Offering included Series F, G, H warrants with exercise prices $0.30, $0.15, $0.225; potential additional $11.5M from warrant exercise is uncertain.","Company intends to appeal delisting by May 14, 2025 but no assurance of success; CEO states commitment to business plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167692,"accession_number":"0001654954-25-004125","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Palatin Technologies receives NYSE American delisting notice; intends to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE Regulation determined to delist PTN for failure to comply with stockholders' equity requirements (Sections 1003(a)(i)-(iii)).","Maximum 18-month compliance plan ended April 10, 2025; Company unable to demonstrate regained compliance.","Company intends to appeal to Listings Qualifications Panel; appeal deadline is April 25, 2025.","Common stock expected to continue trading on NYSE American pending appeal outcome.","No assurance of regaining compliance before the Panel hearing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184973,"accession_number":"0001654954-25-003600","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin reports positive Phase 2 topline results for UC drug PL8177 and obesity combo study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["UC Phase 2: Clinical remission 33% PL8177 vs 0% placebo; clinical response 78% vs 33% (p<0.005) after 8 weeks.","Obesity Phase 2: Co-admin bremelanotide + tirzepatide met primary endpoint with 4.4% weight loss vs 1.6% placebo (p<0.0001).","Obesity: 40% of co-admin group achieved 5% weight loss (p<0.05); low-dose bremelanotide stopped weight regain post-tirzepatide.","Next-gen MC4R long-acting peptides and oral small molecules; IND applications planned for 4Q25, clinical data 1H26.","Licensing discussions for UC program advancing with multiple big pharma companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184972,"accession_number":"0001654954-25-001362","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Palatin enters $6M ATM equity distribution agreement with A.G.P.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At-the-market offering of up to $6.0M of common stock via A.G.P./Alliance Global Partners.","Sales at market prices on NYSE American; commission of 3.0% of gross proceeds.","Offering made under existing S-3 registration statement; prospectus supplement filed Feb 11, 2025.","Company not obligated to sell any shares; can suspend solicitation at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184971,"accession_number":"0001654954-25-001286","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Palatin Technologies announces $4.7M equity offering at $1.00/share, private warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.7M from sale of 2.55M shares at $1.00/share and pre-funded warrants for 2.138M shares.","Private placement includes warrants to purchase 4.688M shares at $1.00, exercisable starting 6 months after issuance for 5.5 years.","Net proceeds will be used for general working capital and corporate purposes.","A.G.P./Alliance Global Partners leads placement; Laidlaw & Co. co-placement agent; 7% cash fee paid.","Company subject to 45-day lockup on additional equity sales and 6-month ban on variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201572,"accession_number":"0001654954-24-015560","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Palatin receives ~$3.4M from warrant exercise; issues new Series C/D warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$3.4M from exercise of 3,907,679 shares at amended price $0.875.","Issued unregistered Series C warrants for 3,907,679 shares and Series D for 1,953,839 shares, both at $0.875/share.","Series C warrants exercisable immediately, 5-year term; Series D exercisable after stockholder approval, 5-year term.","Transaction expected to close Dec 17, 2024; proceeds for working capital and general corporate purposes.","Company agreed to file resale registration statement for inducement warrant shares by Feb 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201571,"accession_number":"0001654954-24-014334","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Palatin Q1 net loss $7.8M; obesity focus with BMT-801 topline Q1 2025; strategic review for non-obesity assets","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.8M ($0.39/share) vs $5.2M a year ago; cash $2.4M at Sep 30, plus $2.5M deferred payment from Vyleesi sale received Nov 2024.","Phase 2 BMT-801 (bremelanotide+tirzepatide) obesity study fully enrolled; topline results expected Q1 2025.","Investment bank retained to explore strategic options for non-obesity programs including DED, UC, glaucoma, retina, and male ED.","Novel MC4R long-acting peptide and oral small molecule IND enabling starts Q1 2025; Phase 1 targeted Q4 2025.","DED program: FDA Type C meeting concluded; subject to funding, Phase 3 enrollment could start Q1 2025."],"consensus_eps_estimate":-1.2558,"consensus_eps_actual":-19.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201570,"accession_number":"0001654954-24-012756","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Palatin receives NYSE American delisting notice for equity deficiency; cure period extended to April 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE American notified Palatin of non-compliance with Section 1003(a)(iii) requiring stockholders' equity of at least $6M after five consecutive years of losses.","Palatin was already non-compliant under Sections 1003(a)(i) and (ii); the new notice adds a third deficiency.","The Exchange accepted Palatin's compliance plan and granted a cure period through April 10, 2025, with quarterly monitoring.","The notice has no immediate effect on trading of PTN common stock, but failure to regain compliance could lead to delisting.","Palatin is exploring multiple funding avenues to achieve compliance and plans future transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201569,"accession_number":"0001654954-24-012549","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Palatin reports FY2024 net loss $29.7M, cash $9.5M; outlines clinical milestones for obesity, DED, ED, UC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2024 $29.7M ($2.02 per share) vs $24.0M ($2.21) prior year; revenue declined as Vyleesi asset sold.","Cash and cash equivalents $9.5M at June 30, 2024; auditor includes going concern explanatory paragraph.","Obesity Phase 2 MC4R+GLP-1 trial enrollment to complete early Q4 2024; topline results expected Q1 2025.","DED Phase 3 MELODY-2/3 trials to start enrollment Q1 2025; topline results anticipated Q4 2025.","Diabetic nephropathy Phase 2 BREAKOUT topline results expected Q4 2024; UC Phase 2 interim readout Q4 2024."],"consensus_eps_estimate":-1.2558,"consensus_eps_actual":-19.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217578,"accession_number":"0001654954-24-011592","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Palatin sets Dec 12, 2024 annual meeting; proxy deadlines announced","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting set for December 12, 2024; record date October 28, 2024.","Rule 14a-8 shareholder proposal deadline: October 21, 2024.","Bylaw director nominations and other proposals due by September 13, 2024.","Meeting date is >30 days from prior year's meeting, triggering extended deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237453,"accession_number":"0001654954-24-008320","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Palatin shareholders elect all seven directors, approve equity plan share increase and say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven directors elected: Carl Spana, John Prendergast, Robert deVeer, J. Stanley Hull, Alan Dunton, Arlene Morris, Anthony Manning.","Amendment to 2011 Stock Incentive Plan approved, increasing share pool by 1,000,000 shares.","KPMG ratified as independent auditor for FY2024 with 6.73M votes for.","Advisory vote on executive compensation (say-on-pay) approved with 925K for, 665K against.","Broker non-votes totaled 5,280,762 on director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237452,"accession_number":"0001654954-24-008011","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Palatin Technologies raises ~$6.1M via warrant inducement with institutional investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters inducement letter; institutional investor exercises existing warrants for $6.1M gross proceeds.","Existing warrants covering 3,233,277 shares exercised at reduced exercise price of $1.88/share.","Company issues new Series A warrants (2,727,273 shares) and Series B warrants (2,122,642 shares) at $1.88 exercise price, five-year term.","Closing expected June 24, 2024; net proceeds for working capital and corporate purposes.","Issuance of 1,624,201 Series B warrant shares subject to stockholder approval under NYSE American rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237451,"accession_number":"0001654954-24-006304","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Palatin Q3 net loss $8.4M; Phase 3 DED study meets pain endpoint, 7 of 11 secondary endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 MELODY-1 for PL9643 in dry eye disease met co-primary pain endpoint (P<0.025) and 7 of 11 secondary endpoints at 12 weeks; rapid onset at 2 weeks.","No revenue in Q3 (Vyleesi rights sold Dec 2023); net loss $8.4M ($0.53 loss per share) vs $8.7M ($0.76) a year ago.","Cash and equivalents $10.0M as of March 31, 2024; expects to fund operations into 2H calendar 2024; raised $10M in registered direct offering in Jan 2024.","Obesity: Phase 2 trial of MCR4 agonist + GLP-1 targeted to start Q2 2024 with topline data in 2H 2024.","Male ED: Phase 2 trial of bremelanotide + PDE5i in non-responders targeted to start Q2 2024, topline expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":4140090.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}